^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Excerpt:
...- Tumor blocks or slides must be available of either primary or metastatic tumor site for c-kit mutation testing...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Sunitinib therapy for melanoma patients with KIT mutations

Excerpt:
Of the 4 evaluable patients with KIT mutations, 1 had a complete remission for 15 months and 2 had partial responses (1- and 7-month duration).
DOI:
10.1158/1078-0432.CCR-11-1987